BactrOMIC is a phenotypic AST platform designed to rapidly and accurately determine antimicrobial susceptibility via actual bacterial growth responses under antibiotic exposure. Produces both quantitative MIC values (Minimum Inhibitory Concentration) and S/I/R categorizations, following CLSI/EUCAST guidelines. Time to result: Phenotypic AST typically takes 18–24 hours via traditional methods BactrOMIC acceleration: While exact numbers for BactrOMIC aren't accessible, rapid systems often deliver results in 4–8 hours, with microfluidic platforms achieving 1–3 hours This positions BactrOMIC within the short-term incubation category — <16 hours as defined by FDA guidelines for accelerated phenotypic AST systems Accepted inputs: Positive blood cultures and isolated colonies from any sterile specimen (urine, sputum, wound). Throughput: Multiple samples can be processed in parallel; though specific device capacity isn't published, comparable systems handle 8–24 samples/run in a few hours (e.g., VITEK, Phoenix) Rapid phenotypic AST technologies consistently aim for ≥90% categorical agreement with gold-standard results Clinical benefits include faster targeted therapy adjustments, reduced broad-spectrum antibiotic usage, and better antimicrobial stewardship True phenotypic testing: Measures growth inhibition, capturing resistance mechanisms that genetics alone may miss. Rapid: Likely supports same-day decision-making, critical for sepsis or severe infections. Automated: Reduces manual steps, minimizes errors, and supports seamless LIS/HIS integration.System Overview
Performance & Turnaround
Sample Types & Throughput
Accuracy & Clinical Impact
Advantages
Clinically relevant data: Includes actual MICs, helping tailor appropriate antibiotic dosages.
